semaglutide or liraglutide for weight loss vs vs GLP-1 Liraglutide vs. Semaglutide | the

Clinical trials conducted in the early 2000s showed modest results, and the compound failed to demonstrate sufficient efficacy to support regulatory approval as a weight-loss medicine

Haass C, Selkoe DJ

He explains the most common symptoms including changes in mood, sleep patterns and food cravings and offers his top five tips for how to cope with the impacts of SAD

As the number of diabetic patients continues to grow globally, this disease has become a major and growing challenge in global public health

Lillys Mounjaro (Tirzepatide), a GIP/GLP-1 Dual Agonist, Demonstrated Cardiovascular Protection in Landmark Head-to-Head Trial, Reinforcing Its Benefit in Patients with Type 2 Diabetes and Heart Disease (Eli Lilly and Company, accessed 19 August 2025)

The most common side effects of semaglutide are nausea, vomiting, constipation, and diarrhea